These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies. Van Damme A; Chuah MK; Collen D; VandenDriessche T Semin Thromb Hemost; 2004 Apr; 30(2):185-95. PubMed ID: 15118930 [TBL] [Abstract][Full Text] [Related]
5. Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns. Lillicrap D Haematologica; 2000 Oct; 85(10 Suppl):108-11; discussion 111-2. PubMed ID: 11187861 [TBL] [Abstract][Full Text] [Related]
6. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610 [TBL] [Abstract][Full Text] [Related]
7. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Rawle FE; Lillicrap D Semin Thromb Hemost; 2004 Apr; 30(2):205-13. PubMed ID: 15118932 [TBL] [Abstract][Full Text] [Related]
8. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137 [TBL] [Abstract][Full Text] [Related]
11. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis. DiMichele D; Kroner B; Haematologica; 2000 Oct; 85(10 Suppl):40-2; discussion 42-4. PubMed ID: 11187869 [TBL] [Abstract][Full Text] [Related]
13. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen]. Iizuka A Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995 [No Abstract] [Full Text] [Related]
14. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609 [TBL] [Abstract][Full Text] [Related]
15. Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. Liu L; Mah C; Fletcher BS Mol Ther; 2006 May; 13(5):1006-15. PubMed ID: 16464640 [TBL] [Abstract][Full Text] [Related]
16. Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice. Zhang TP; Jin DY; Wardrop RM; Gui T; Maile R; Frelinger JA; Stafford DW; Monahan PE Gene Ther; 2007 Mar; 14(5):429-40. PubMed ID: 17066096 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and immune tolerance coagulation Factors VIII and IX. Rup B Dev Biol (Basel); 2003; 112():55-9. PubMed ID: 12762504 [TBL] [Abstract][Full Text] [Related]
19. Gene therapy for hemophilia A. Gan SU; Calne RY Discov Med; 2006 Oct; 6(35):198-202. PubMed ID: 17234142 [TBL] [Abstract][Full Text] [Related]
20. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences. Chuah M; Vandendriessche T Verh K Acad Geneeskd Belg; 2007; 69(5-6):315-34. PubMed ID: 18351211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]